Meanwhile, the targeted drugs used to treat NPC in clinical trials mainly consist of EGFR inhibitor (Cetuximab, Nimotuzumab), VEGF/VEGFR inhibitor (Bevacizumab, Endostar). The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.